96 results on '"Muñoz Fernandez MA"'
Search Results
2. Long-term evolution in liver disease markers and immune and lipid profiles in vertically HIV/HCV-coinfected youths with sustained viral response after direct-acting antivirals therapy
- Author
-
Tarancon-Diez, Laura, Carrasco, Itzíar, Jiménez de Ory, Santiago, Berzosa Sánchez, Arantxa, Hernanz-Lobo, Alicia, Montero-Alonso, Marta, Laguno, Montserrat, Bernardino, Jose I., López-Cortés, Luis, Aldamiz-Echevarría, Teresa, Collado, Pilar, Bisbal, Otilia, Samperiz, Gloria, Gavilán, César, Ríos, Mª José, Ibarra, Sofía, Navarro, María Luisa, and Muñoz-Fernández, Mª Ángeles
- Published
- 2023
- Full Text
- View/download PDF
3. Synthesis of bow-tie carbosilane dendrimers and their HIV antiviral capacity: A comparison of the dendritic topology on the biological process
- Author
-
Gutierrez-Ulloa, Carlos E., Sepúlveda-Crespo, Daniel, García-Broncano, Pilar, Malý, Marek, Muñoz-Fernández, Mª Angeles, de la Mata, Fco Javier, and Gómez, Rafael
- Published
- 2019
- Full Text
- View/download PDF
4. Polyanionic carbosilane dendrimers prevent hepatitis C virus infection in cell culture
- Author
-
Sepúlveda-Crespo, Daniel, Jiménez, José Luis, Gómez, Rafael, De La Mata, Francisco Javier, Majano, Pedro L., Muñoz-Fernández, Ma Ángeles, and Gastaminza, Pablo
- Published
- 2017
- Full Text
- View/download PDF
5. Prevention vaginally of HIV-1 transmission in humanized BLT mice and mode of antiviral action of polyanionic carbosilane dendrimer G2-S16
- Author
-
Sepúlveda-Crespo, Daniel, Serramía, María Jesús, Tager, Andrew M., Vrbanac, Vladimir, Gómez, Rafael, De La Mata, Francisco Javier, Jiménez, José Luis, and Muñoz-Fernández, Mª Ángeles
- Published
- 2015
- Full Text
- View/download PDF
6. Polyanionic carbosilane dendrimer-conjugated antiviral drugs as efficient microbicides: Recent trends and developments in HIV treatment/therapy
- Author
-
Sepúlveda-Crespo, Daniel, Gómez, Rafael, De La Mata, Francisco Javier, Jiménez, José Luis, and Muñoz-Fernández, Mª. Ángeles
- Published
- 2015
- Full Text
- View/download PDF
7. In vivo delivery of siRNA to the brain by carbosilane dendrimer
- Author
-
Serramía, Mª Jesús, Álvarez, Susana, Fuentes-Paniagua, Elena, Clemente, Maria Isabel, Sánchez-Nieves, Javier, Gómez, Rafael, de la Mata, Javier, and Muñoz-Fernández, Mª Ángeles
- Published
- 2015
- Full Text
- View/download PDF
8. Threshold Ferritin Concentrations Reflecting Early Iron Deficiency Based on Hepcidin and Soluble Transferrin Receptor Serum Levels in Patients with Absolute Iron Deficiency
- Author
-
Tarancon-Diez, Laura, primary, Genebat, Miguel, additional, Roman-Enry, Manuela, additional, Vázquez-Alejo, Elena, additional, Espinar-Buitrago, Maria de la Sierra, additional, Leal, Manuel, additional, and Muñoz-Fernandez, Mª Ángeles, additional
- Published
- 2022
- Full Text
- View/download PDF
9. Synergistic activity profile of carbosilane dendrimer G2-STE16 in combination with other dendrimers and antiretrovirals as topical anti-HIV-1 microbicide
- Author
-
Sepúlveda-Crespo, Daniel, Lorente, Raquel, Leal, Manuel, Gómez, Rafael, De la Mata, Francisco J., Jiménez, José Luis, and Muñoz-Fernández, Mª Ángeles
- Published
- 2014
- Full Text
- View/download PDF
10. Early antiretroviral therapy initiation effect on metabolic profile in vertically HIV-1-infected children
- Author
-
Tarancón-Diez, Laura, primary, Rull, Anna, additional, Herrero, Pol, additional, Vazquez-Alejo, Elena, additional, Peraire, Joaquim, additional, Guillén, Sara, additional, Navarro-Gomez, Maria Luisa, additional, Viladés, Consuelo, additional, Muñoz-Fernandez, Mª Ángeles, additional, and Vidal, Francesc, additional
- Published
- 2021
- Full Text
- View/download PDF
11. Binding Properties of Water-Soluble Carbosilane Dendrimers
- Author
-
Pedziwiatr, Elzbieta, Shcharbin, Dzmitry, Chonco, Louis, Ortega, Paula, Javier de la Mata, F., Gómez, Rafael, Klajnert, Barbara, Bryszewska, Maria, and Muñoz-Fernandez, Ma Angeles
- Published
- 2009
- Full Text
- View/download PDF
12. A new tool for the paediatric HIV research: general data from the Cohort of the Spanish Paediatric HIV Network (CoRISpe)
- Author
-
de Jose Ma Isabel, Jiménez de Ory Santiago, Espiau Maria, Fortuny Claudia, Navarro Ma Luisa, Soler-Palacín Pere, and Muñoz-Fernandez Ma Angeles
- Subjects
HIV paediatric cohort ,Paediatric HIV infection ,Spanish HIV HGM biobank ,Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract There are approximately from 1,100 to 1,200 HIV-infected children in a follow-up in Spain. In 2008 an open, multicentral, retrospective and prospective Cohort of the Spanish Paediatric HIV Network (CoRISpe) was founded. The CoRISpe is divided into the node 1 and node 2 representing geographically almost the whole territory of Spain. Since 2008 seventy-five hospitals have been participating in the CoRISpe. All the retrospective data of the HIV-infected children have been kept in the CoRISpe since 1995 and prospective data since 2008. In this article we are going to present the notion of CoRISpe, its role, the structure, how the CoRISpe works and the process how a child is transferred from Paediatric to Adults Units. The main objective of the CoRISpe is to contribute to furthering scientific knowledge on paediatric HIV infection by providing demographic, sociopsychological, clinical and laboratory data from HIV-infected paediatric patients. Its aim is to enable high-quality research studies on HIV-infected children.
- Published
- 2013
- Full Text
- View/download PDF
13. Paediatric research in Spain: Challenges and priorities. INVEST-AEP Platform
- Author
-
Calvo C, Sainz T, Codoñer-Franch P, Santiago B, García-García ML, García Vera C, Muñoz-Fernandez MA, Pérez-Martínez A, Rivero I, Fernandez Pérez C, Mejías A, Martinón-Torres F, and Cabañas F
- Subjects
Research ,Training ,Paediatrics ,Network - Abstract
Research is the cornerstone of medical progress. Paediatric research has its own nuances and represents an additional challenge due to the intrinsic characteristics of the paediatric population compared with adults. Despite the tremendous importance of childhood health and its impact during adulthood, society is still not convinced about the importance of conducting research in paediatrics. This also applies to paediatricians themselves, who think about research as a discipline that does not directly involve them. The Spanish Academy of Paediatrics has developed a specific research platform-INVEST-AEP-to try to help and answer the challenges associated with paediatric research in the society This article reflects the current status of paediatric research in Spain, and the goals achieved over the last few years due to the effort of paediatric researchers. In addition, a deeper analysisis provided as regards: a) the barriers that represent a hurdle for the development of broad and competitive paediatric research in our day to day work; b) the limited incentives and specific pre- and post-doctoral training; c) the high clinical burden for paediatricians or; d) the lack of specific infrastructure and dedicated funding for paediatrics. The mission, vision and values of INVEST-AEP are to develop an accessible roadmap for the development and implementation of paediatric research in Spain for the next few years. (C) 2018 Asociacion Espanola de Pediatria. Published by Elsevier Espana, S.L.U.
- Published
- 2018
14. Immune Correlates of Natural HIV Elite Control and Simultaneous HCV Clearance—Supercontrollers
- Author
-
Dominguez-Molina, Beatriz, primary, Ferrando-Martinez, Sara, additional, Tarancon-Diez, Laura, additional, Hernandez-Quero, Jose, additional, Genebat, Miguel, additional, Vidal, Francisco, additional, Muñoz-Fernandez, Mª Angeles, additional, Leal, Manuel, additional, Koup, Richard, additional, and Ruiz-Mateos, Ezequiel, additional
- Published
- 2018
- Full Text
- View/download PDF
15. A New Possible Mechanism of Human Immunodeficiency Virus Type 1 Infection of Neural Cells
- Author
-
Álvarez Losada, Susana, Cantó-Nogués, Carmen, and Muñoz-Fernández, Ma Angeles
- Published
- 2002
- Full Text
- View/download PDF
16. Predictive factors of virological success to salvage regimens containing protease inhibitors in HIV-1 infected children
- Author
-
Soriano Vincent, Mellado Ma José, de José Ma Isabel, Bellón José, de Mendoza Carmen, Larru Beatriz, Muñoz-Fernandez Ma Angeles, and Ramos José T
- Subjects
Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Background The impact of HIV drug resistance mutations in salvage therapy has been widely investigated in adults. By contrast, data available of predictive value of resistance mutations in pediatric population is scarce. Methods A multicenter, retrospective, observational study was conducted in children who received rescue salvage antiretroviral therapy after virologic failure. CD4 counts and viral load were determined at baseline and 6 months after rescue intervention. Genotypic HIV-1 resistance test and virtual phenotype were assessed at baseline. Results A total of 33 children met the inclusion criteria and were included in the analysis. The median viral load (VL) and median percentage of CD4+ at baseline was 4.0 HIV-RNA log copies/ml and 23.0% respectively. The median duration that children were taking the new rescue regimen was 24.3 weeks (23.8–30.6). Overall, 47% of the 33 children achieved virological response at 24 weeks. When we compared the group of children who achieved virological response with those who did not, we found out that mean number of PI related mutations among the group of responders was 3.8 vs. 5.4 (p = 0.115). Moreover, the mean number of susceptible drugs according to virtual phenotype clinical cut-off for maximal virologic response was 1.7 vs. 0.8 and mean number of susceptible drugs according to virtual phenotype cut-off for minimal virlologic response was 2.7 vs. 1.3 (p < 0.01 in all cases). Eighteen children were rescued with a regimen containing a boosted-PI and virological response was significantly higher in those subjects compared with the others (61.1% vs. 28.6%, p < 0.01). Conclusion Salvage treatment containing ritonavir boosted-PIs in children with virological failure was very efficient. The use of new tools as virtual phenotype could help to improve virologic success in pediatric population.
- Published
- 2007
- Full Text
- View/download PDF
17. Neurocognition and quality of life after reinitiating antiretroviral therapy in children randomized to planned treatment interruption
- Author
-
Ananworanich, J, Melvin, D, Amador, Jt, Childs, T, Medin, G, Boscolo, V, Compagnucci, A, Kanjanavanit, S, Montero, S, Gibb, Dm, PENTA 11 Study Group including Aboulker, J, Babiker, A, Belfrage, E, Bernardi, S, Bologna, R, Burger, D, Butler, K, Castelli Gattinara, G, Castro, H, Clayden, P, Cressey, T, Darbyshire, Jh, Debré, M, de Groot, R, della Negra, M, di Biagio, A, De Rossi, A, Duicelescu, D, Faye, A, Giaquinto, C, Giacomet, V, Grosch Wörner, I, Hainault, M, Klein, N, Lallemant, M, Levy, J, Lyall, H, Marczynska, M, Marques, L, Mardarescu, M, Mellado Peña MJ, Nadal, D, Nastouli, E, Naver, L, Niehues, T, Peckham, C, Pillay, D, Popieska, J, Ramos Amador JT, Rojo Conejo, P, Rosado, L, Rosso, R, Rudin, C, Scherpbier, Hj, Sharland, M, Stevanovic, M, Thorne, C, Tovo, Pier Angelo, Tudor Williams, G, Turkova, A, Valerius, N, Volokha, A, Walker, As, Welch, S, Wintergerst, U, Aboulker, Jp, Burger, Dm, Green, H, Harper, L, Mofenson, L, Moye, J, Saïdi, Y, Cressey, Tr, Jacqz Aigrain, E, Khoo, S, Regazzi, M, Tréluyer, Jm, Ngo Giang Huong, N, Muñoz Fernandez MA, Hill, C, Lepage, P, Pozniak, A, Vella, S, Chêne, G, Vesikari, T, Hadjou, G, Léonardo, S, Riault, Y, Bleier, J, Buck, L, Duong, T, Farrelly, L, Forcat, S, Harrison, L, Horton, J, Johnson, D, Taylor, C, Chalermpantmetagul, S, Peongjakta, R, Khamjakkaew, W, Than in at, K, Chailert, S, Jourdain, G, Le Coeur, S, Floret, D, Costanzo, P, Le Thi TT, Monpoux, F, Mellul, S, Caranta, I, Boudjoudi, N, Firtion, G, Denon, M, Charlemaine, E, Picard, F, Hellier, E, Heuninck, C, Damond, F, Alexandre, G, Tricoire, J, Antras, M, Lachendowier, C, Nicot, F, Krivine, A, Rivaux, D, Notheis, G, Strotmann, G, Schlieben, S, Rampon, O, Zanchetta, M, Ginocchio, F, Viscoli, C, Martino, A, Pontrelli, G, Baldassar, S, Concato, C, Mazza, A, Rossetti, G, Dobosz, S, Oldakowska, A, Popielska, J, Kaflik, M, Stanczak, J, Stanczack, G, Dyda, T, Kruk, M, González Tomé MI, Delgado García, R, Fernandez Gonzalez MT, Mellado Peña, M, Martín Fontelos, P, Garcia Mellado MI, Medina, Af, Ascencion, B, Garcia Bermejo, I, Navarro Gomez DM, Saavedra, J, Prieto, C, Jimenez, Jl, Garcia Torre, A, de José Gómez MI, García Rodriguez MC, Moreno Pérez, D, Núñez Cuadros, E, Asensi Botet, F, Otero Reigada, C, Pérez Tamarit MD, Vilalta, R, Molina Moreno JM, Rainer, T, Schupbach, J, Rutishauser, M, Bunupuradah, T, Butterworth, O, Phasomsap, C, Prasitsuebsai, W, Chuanjaroen, T, Jupimai, T, Ubolyam, S, Phanuphak, P, Puthanakit, T, Pancharoen, C, Mai, C, Namwong, T, Punsakoon, W, Payakachat, S, Chutima, D, Raksasang, M, Foster, C, Hamadache, D, Campbell, S, Newbould, C, Monrose, C, Abdulla, A, Walley, A, Patel, D, Kaye, S, Seery, P, Rankin, A, Wildfire, A, Novelli, V, Shingadia, D, Moshal, K, Flynn, J, Clapson, M, Allen, A, Spencer, L, Rackstraw, C, Ward, B, Parkes, K, Depala, M, Jacobsen, M, Poulsom, H, Barkley, L, Miah, J, Lurie, P, Keane, C, Mcmaster, P, Phipps, M, Orendi, J, Farmer, C, Liebeschuetz, S, Sodeinde, O, Wong, S, Bostock, V, Heath, Y, Scott, S, Gandhi, K, Lewis, P, Daglish, J, Miles, K, Summerhill, L, Subramaniam, B, Weiner, L, Famiglietti, M, Rana, S, Yu, P, Roa, J, Puga, A, Haerry, A., AII - Amsterdam institute for Infection and Immunity, Paediatric Infectious Diseases / Rheumatology / Immunology, and Global Health
- Subjects
0301 basic medicine ,Male ,Pediatrics ,medicine.medical_specialty ,antiretroviral therapy ,children ,HIV ,neurocognition ,neurodevelopment ,quality of life ,treatment interruption ,Immunology and Allergy ,Immunology ,Infectious Diseases ,Adolescent ,lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4] ,Antiretroviral Therapy ,HIV Infections ,Standard score ,03 medical and health sciences ,0302 clinical medicine ,Cognition ,Acquired immunodeficiency syndrome (AIDS) ,Antiretroviral Therapy, Highly Active ,Memory span ,Medicine ,Humans ,Highly Active ,030212 general & internal medicine ,Child ,Wechsler Intelligence Scale for Children ,business.industry ,Wechsler Adult Intelligence Scale ,medicine.disease ,030112 virology ,lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4] ,Treatment Outcome ,Anti-Retroviral Agents ,Test score ,Mann–Whitney U test ,Quality of Life ,Female ,business ,Neurocognitive - Abstract
Item does not contain fulltext OBJECTIVE: Understanding the effects of antiretroviral treatment (ART) interruption on neurocognition and quality of life (QoL) are important for managing unplanned interruptions and planned interruptions in HIV cure research. DESIGN: Children previously randomized to continuous (continuous ART, n = 41) vs. planned treatment interruption (PTI, n = 47) in the Pediatric European Network for Treatment of AIDS (PENTA) 11 study were enrolled. At study end, PTI children resumed ART. At 1 and 2 years following study end, children were assessed by the coding, symbol search and digit span subtests of Wechsler Intelligence Scale for Children (6-16 years old) or Wechsler Adult Intelligence Scale (>/=17 years old) and by Pediatrics QoL questionnaires for physical and psychological QoL. Transformed scaled scores for neurocognition and mean standardized scores for QoL were compared between arms by t-test and Mann-Whitney U test, respectively. Scores indicating clinical concern were compared (
- Published
- 2016
18. Using CD4 percentage and age to optimize pediatric antiretroviral therapy initiation
- Author
-
Yin, D.E., Warshaw, M.G., Miller, W.C., Castro, H., Fiscus, S.A., Harper, L.M., Harrison, L.J., Klein, N.J., Lewis, J., Melvin, A.J., Tudor Williams, G., Mckinney, R.E., Brouwers, P., Costello, D., Ferguson, E., Fiscus, S., Hodge, J., Hughes, M., Jennings, C., Melvin, A., Mckinney, R., Mofenson, L., Warshaw, M., Smith, M., Spector, S., Stiehm, E., Toye, M., Yogev, R., Babiker, A., Compagnucci, A., De Rossi, A., Giaquinto, C., Darbyshire, J., Debré, M., Gibb, D., Harper, L., Harrison, L., Klein, N., Pillay, D., Saidi, Y., Walker, A., Brody, B., Hill, C., Lepage, P., Modlin, J., Poziak, A., Rein, M., Robb, M., Fleming, T., Vella, S., Kim, K., Bologna, R., Mecikovsky, D., Pineda, N., Sen, L., Mangano, A., Marino, S., Galvez, C., Deluchi, G., Zöhrer, B., Zenz, W., Daghofer, E., Pfurtscheller, K., Pabst, B., Gomez, M., Mcneil, P., Jervis, M., Whyms, I., Kwolfe, D., Scott, S., Mussi Pinhata MM, Issac, M., Cervi, M., Negrini, B., Matsubara, T., de Souza CB, Gabaldi, J., Oliveira, R., Sapia, M., Abreu, T., Evangelista, L., Pala, A., Fernandes, I., Farias, I., Melo M, D.F., Carreira, H., Lira, L., Della Negra, M., Queiroz, W., Lian, Y., Pacola, D., Pinto, J., Ferreira, F., Kakehasi, F., Martins, L., Diniz, A., Lobato, V., Diniz, M., Cleto, S., Costa, S., Romeiro, J., Dollfus, C., Tabone, M., Courcoux, M., Vaudre, G., Dehée, A., Schnuriger, A., Le Gueyades, N., De Bortoli, C., Méchinaud, F., Reliquet, V., Arias, J., Rodallec, A., André, E., Falconi, I., Le Pelletier, A., Monpoux, F., Cottalorda, J., Mellul, S., Lachassinne, E., Galimand, J., Rouzioux, C., Chaix, M., Benabadji, Z., Pourrat, M., Firtion, G., Rivaux, D., Denon, M., Boudjoudi, N., Nganzali, F., Krivine, A., Méritet, J., Delommois, G., Norgeux, C., Guérin, C., Floch, C., Marty, L., Hichou, H., Tournier, V., Faye, A., Le Moal, I., Sellier, M., Dehache, L., Damond, F., Leleu, J., Beniken, D., Alexandre Castor, G., Neubert, J., Niehues, T., Laws, H., Huck, K., Gudowius, S., Siepermann, K., Loeffler, H., Bellert, S., Ortwin, A., Notheis, G., Wintergerst, U., Hoffman, F., Werthmann, A., Seyboldt, S., Schneider, L., Bucholz, B., Feiterna Sperling, C., Peiser, C., Nickel, R., Schmitz, T., Piening, T., Müller, C., Warncke, G., Wigger, M., Neubauer, R., Butler, K., Chong, A., Boulger, T., Menon, A., O'Connell, M., Barrett, L., Rochford, A., Goode, M., Hayes, E., Mcdonagh, S., Walsh, A., Doyle, A., Fanning, J., O'Connor, M., Byrne, M., O'Sullivan, N., Hyland, E., Giacomet, V., Viganò, A., Colombo, I., Trabattoni, D., Berzi, A., Badolato, R., Schumacher, F., Bennato, V., Brusati, M., Sorlini, A., Spinelli, E., Filisetti, M., Bertulli, C., Rampon, O., Zanchetta, M., Mazza, A., Stringari, G., Rossetti, G., Bernardi, S., Martino, A., Castelli Gattinara, G., Palma, P., Pontrelli, G., Tchidjou, H., Furcas, A., Frillici, C., Mazzei, A., Zoccano, A., Concato, C., Duiculescu, D., Oprea, C., Tardei, G., Abaab, F., Mardarescu, M., Draghicenoiu, R., Otelea, D., Alecsandru, L., Matusa, R., Rugina, S., Ilie, M., Netescu, S., Florea, C., Voicu, E., Poalelungi, D., Belmega, C., Vladau, L., Chiriac, A., Ramos Amador JT, Gonzalez Tomé MI, Rojo Conejo, P., Fernandez, M., Delgado Garcia, R., Ferrari, J., Garcia Lopez, M., Mellado Peña MJ, Martin Fontelos, P., Jimenez Nacher, I., Muñoz Fernandez MA, Jimenez, J., García Torre, A., Penin, M., Pineiro Perez, R., Garcia Mellado, I., Finn, A., Lajeunesse, M., Hutchison, E., Usher, J., Ball, L., Dunn, M., Sharland, M., Doerholt, K., Storey, S., Donaghy, S., Chakraborty, R., Wells, C., Buckberry, K., Rice, P., Mcmaster, P., Butler, P., O'Connell C, R., Shenton, J., Haley, H., Orendi, J., Stroobant, J., Navarante, L., Archer, P., Mazhude, C., Scott, D., O'Connell, R., Wong, J., Boddy, G., Shackley, F., Lakshman, R., Hobbs, J., Ball, G., Kudesia, G., Bane, J., Painter, D., Sloper, K., Shah, V., Cheng, A., Aali, A., Ball, C., Hawkins, S., Nayagam, D., Waters, A., Doshi, S., Liebeschuetz, S., Sodiende, B., Shingadia, D., Wong, S., Swan, J., Shah, Z., Collinson, A., Hayes, C., King, J., O'Connor, K., Lyall, H., Fidler, K., Walters, S., Foster, C., Hamadache, D., Newbould, C., Monrose, C., Campbell, S., Yeung, S., Cohen, J., Martinez Allier, N., Melvin, D., Dodge, J., Welch, S., Tatum, G., Gordon, A., Kaye, S., Muir, D., Patel, D., Novelli, V., Moshal, K., Lambert, J., Flynn, J., Farrelly, L., Clapson, M., Spencer, L., Depala, M., Jacobsen, M., Segal, S., Pollard, A., Kelly, D., Yeadon, S., Ohene Kena, B., Peng, Y., Dong, T., Jeffries, K., Snelling, M., Smyth, A., Smith, J., Ward, B., Jungmann, E., Ryan, C., Swaby, K., Buckton, A., Smit, E., Abrams, E., Champion, S., Fernandez, A., Calo, D., Garrovillo, L., Swaminathan, K., Alford, T., Frere, M., Navarra, J., Borkowsky, W., Deygoo, S., Hastings, T., Akleh, S., Ilmet, T., Mohan, K., Bowen, G., Emmanuel, P., Lujan Zimmerman, J., Rodriguez, C., Johnson, S., Marion, A., Graisbery, C., Casey, D., Lewis, G., Guzman Cottrill, J., Croteau, R., Acevedo Flores, M., Gonzalez, M., Angeli, L., Fabregas, L., Valentin, P., Weiner, L., Contello, K., Holz, W., Butler, M., Nachman, S., Kelly, M., Ferraro, D., Rana, S., Reed, C., Yeagley, E., Malheiro, A., Roa, J., Neely, M., Kovacs, A., Homans, J., Rodriguez Lozano, Y., Puga, A., Talero, G., Sellers, R., Lawrence, R., Weinberg, G., Murante, B., Laverty, S., Deveikis, A., Batra, J., Chen, T., Michalik, D., Deville, J., Elkins, K., Marks, S., Jackson Alvarez, J., Palm, J., Fineanganofo, I., Keuth, M., Deveikis, L., Tomosada, W., Van Dyke, R., Alchediak, T., Silio, M., Borne, C., Bradford, S., Eloby Childress, S., Nguyen, K., Rathore, M., Alvarez, A., Mirza, A., Mahmoudi, S., Burke, M., Febo, I., Lugo, L., Santos, R., Church, J., Dunaway, T., Rodier, C., Flynn, P., Patel, N., Discenza, S., Donohoe, M., Luzuriaga, K., Picard, D., Kline, M., Paul, M., Shearer, W., Mcmullen, C., Chadwick, E., Cagwin, E., Kabat, K., Dieudonne, A., Palumbo, P., Johnson, J., Gaur, S., Cerracchio, L., Foca, M., Jurgrau, A., Vasquez Bonilla, S., Silva, G., Gershon, A., Sullivan, J., Bryson, Y., Frenkel, L., Nelson, J., Aboulker, J., Hadjou, G., Léonardo, S., Riault, Y., Saïdi, Y., Buck, L., Forcat, S., Horton, J., Johnson, D., Moore, S., Taylor, C., Collins, D., Buskirk, S., Kamara, P., Nesel, C., Johnson, M., Ferreira, A., Tutko, J., Sprenger, H., Britto, P., Powell, C., Dersimonian, R., Handelsman, E., Ananworanich, J., Belfrage, E., Blanche, S., Bohlin, A., Burger, D., Clayden, P., De Groot, R., Di Biagio, A., Grosch Wörner, I., Hainault, M., Lallemant, M., Levy, J., Marczynska, M., Mellado Pena MJ, Nadal, D., Naver, L., Peckham, C., Popieska, J., Rosado, L., Rosso, R., Rudin, C., Scherpbier, H., Stevanovic, M., Thorne, C., Tovo, P., Valerius, N., Poole, C., Cole, S., and Mcculloh, R.J.
- Subjects
CD4-Positive T-Lymphocytes ,Male ,medicine.medical_treatment ,HIV (FISIOLOGIA) ,lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4] ,Human immunodeficiency virus (HIV) ,HIV Infections ,medicine.disease_cause ,Treatment failure ,Settore BIO/13 - Biologia Applicata ,Antiretroviral Therapy, Highly Active ,immunologic ,Child ,HIV ,child ,reconstitution ,treatment failure ,Adolescent ,Anti-HIV Agents ,CD4 Lymphocyte Count ,Child, Preschool ,Female ,Follow-Up Studies ,HIV-1 ,Humans ,Infant ,Infant, Newborn ,Follow up studies ,Immunosuppression ,medicine.medical_specialty ,Settore MED/17 - Malattie Infettive ,Antiretroviral Therapy ,World health ,Article ,Internal medicine ,medicine ,Highly Active ,Preschool ,Settore MED/04 - Patologia Generale ,business.industry ,Disease progression ,Settore MED/46 - Scienze Tecniche di Medicina di Laboratorio ,Newborn ,Antiretroviral therapy ,Confidence interval ,lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4] ,Immunologic ,Reconstitution ,Pediatrics, Perinatology and Child Health ,Immunology ,business - Abstract
BACKGROUND: Quantifying pediatric immunologic recovery by highly active antiretroviral therapy (HAART) initiation at different CD4 percentage (CD4%) and age thresholds may inform decisions about timing of treatment initiation. METHODS: HIV-1-infected, HAART-naive children in Europe and the Americas were followed from 2002 through 2009 in PENPACT-1. Data from 162 vertically infected children, with at least World Health Organization “mild” immunosuppression and CD4% RESULTS: Seventy-two percent of baseline immunosuppressed children recovered to normal within 4 years. Compared with “severe” immunosuppression, more children with “mild” immunosuppression (difference 36%, 95% confidence interval [CI]: 22% to 49%) or “advanced” immunosuppression (difference 20.8%, 95% CI: 5.8% to 35.9%) recovered a normal CD4%. For each 5-year increase in baseline age, the proportion of children achieving a normal CD4% declined by 19% (95% CI: 11% to 27%). Combining baseline CD4% and age effects resulted in >90% recovery when initiating HAART with “mild” immunosuppression at any age or “advanced” immunosuppression at age CONCLUSIONS: Initiating HAART at higher CD4% and younger ages maximizes potential for immunologic recovery. Guidelines should weigh immunologic benefits against long-term risks.
- Published
- 2014
19. Dendronized PLGA nanoparticles with anionic carbosilane dendrons as antiviral agents against HIV infection
- Author
-
Galán, Marta, primary, Fornaguera, Cristina, additional, Ortega, Paula, additional, Calderó, Gabriela, additional, Lorente, Raquel, additional, Jimenez, Jose Luis, additional, Mata, Javier de la, additional, Muñoz-Fernandez, Ma Angeles, additional, Solans, Conxita, additional, and Gómez, Rafael, additional
- Published
- 2016
- Full Text
- View/download PDF
20. The immunological and virological consequences of planned treatment interruptions in children with HIV infection
- Author
-
Klein, Nigel, Sefe, Delali, Mosconi, Ilaria, Zanchetta, Marisa, Castro, Hannah, Jacobsen, Marianne, Jones, Hannah, Bernardi, Stefania, Pillay, Deenan, Giaquinto, Carlo, Walker, A. Sarah, Gibb, Diana M., De Rossi, Anita, Paediatric, European Network for Treatment of AIDS 11 Trial Team including Aboulker JP, Ananworanich, J, Babiker, A, Belfrage, E, Bernardi, S, Blanche, S, Bohlin, Ab, Bologna, R, Burger, Dm, Butler, K, Castelli Gattinara, G, Castro, H, Clayden, P, Compagnucci, A, Darbyshire, Jh, Debré, M, Faye, A, de Groot, R, della Negra, M, Duiculescu, D, Giaquinto, C, Gibb, Dm, Grosch Wörner, I, Hainault, M, Harper, L, Klein, N, Lallemant, M, Levy, J, Lyall, H, Marczynska, M, Mardarescu, M, Mellado Peña, Mj, Nadal, D, Niehues, T, Peckham, C, Pillay, D, Ramos Amador, Jt, Rosado, L, Rosso, R, Rudin, C, Saidi, Y, Scherpbier, Hj, Sharland, M, Stevanovic, M, Thorne, C, Tovo, Pier Angelo, Tudor Williams, G, Valerius, N, Walker, As, Welch, S, Wintergerst, U, Aboulker, Jp, Mofenson, L, Moye, J, Saïdi, Y, Cressey, Tr, Jacqz Aigrain, E, Khoo, S, Tréluyer, Jm, De Rossi, A, Ngo Giang Huong, N, Muñoz Fernandez, Ma, Hill, C, Lepage, P, Pozniak, A, Vella, S, Hadjou, G, Léonardo, S, Riault, Y, Buck, L, Farrelly, L, Forcat, S, Harrison, L, Horton, J, Johnson, D, Moore, S, Taylor, C, Chalermpantmetagul, S, Peongjakta, R, Chailert, S, Fregonese, F, Jourdain, G, Butler, D, Carlton, C, Collins, D, Kao, G, Van Buskirk, S, Watson, S, Corradini, S, Floret, D, Le Thi, Tt, Monpoux, F, Cottalorda, J, Lefebvre, Jc, Mellul, S, Boudjoudi, N, Firtion, G, Denon, M, Picard, F, Beniken, D, Damond, F, Alexandre, G, Tricoire, J, Nicot, F, Krivine, A, Rivaux, D, Chaix, Ml, Notheis, G, Strotmann, G, Schlieben, S, Rampon, O, Zanchetta, M, Ginocchio, F, Viscoli, C, Martino, A, Pontrelli, G, Concato, C, Mazza, A, Rossetti, G, Dobosz, S, Oldakowska, A, Popielska, J, Kaflik, M, Stanczak, J, Stanczack, G, Dyda, T, González Tomé, Mi, Delgado García, R, Fernandez Gonzalez, Mt, Martín Fontelos, P, Piñeiro Pérez, R, Penin, M, Garcia Mellado, I, Medina, Af, Ascencion, B, Garcia Bermejo, I, Garcia Vela, Ja, Martin Rubio, I, Gurbindo, D, Navarro Gomez, Ml, Jimenez, Jl, Garcia Torre, A, José Gómez, Mi, García Rodriguez, Mc, Moreno Pérez, D, Núñez Cuadros, E, Asensi Botet, F, Pérez, A, Pérez Tamarit, Md, Gobernado Serrano, M, Gonzales Molina, A, Kalhert, C, Dobrovoljac, M, Berger, C, Nobile, G, Reinhard, S, Schupbach, J, Bunupuradah, T, Puthanakit, T, Pancharoen, C, Butterworth, O, Phasomsap, C, Jupimai, T, Ubolyam, S, Phanuphak, P, Mai, C, Kanjanavanit, S, Namwong, T, Chutima, D, Raksasang, M, Foster, C, Hamadache, D, Campbell, S, Newbould, C, Monrose, C, Patel, D, Kaye, S, Seery, P, Wildfire, A, Novelli, V, Shingadia, D, Moshal, K, Flynn, J, Clapson, M, Allen, A, Spencer, L, Depala, M, Jacobsen, M, Mcmaster, P, Phipps, M, Orendi, J, Farmer, C, Liebeschuetz, S, Sodeinde, O, Wong, S, Heath, Y, Scott, S, Gandhi, K, Lewis, P, Daglish, J, Weiner, L, Famiglietti, M, Rana, S, Yu, P, Roa, J, Puga, A, Haerry, A, and Inma, A.
- Subjects
CD31 ,Genetics and Molecular Biology (all) ,CD4-Positive T-Lymphocytes ,Time Factors ,T-CELL RECONSTITUTION ,ACTIVE ANTIRETROVIRAL THERAPY, STRUCTURED TREATMENT INTERRUPTION, T-CELL RECONSTITUTION, HIV-1-INFECTED CHILDREN, IMMUNE RECONSTITUTION, THYMIC OUTPUT, 1-INFECTED CHILDREN ,Adolescent ,Anti-Retroviral Agents ,CD8-Positive T-Lymphocytes ,Child ,Child, Preschool ,Drug Administration Schedule ,HIV Infections ,Humans ,Immunophenotyping ,Lymphocyte Count ,Treatment Outcome ,Viral Load ,Agricultural and Biological Sciences (all) ,Biochemistry, Genetics and Molecular Biology (all) ,Medicine (all) ,Biochemistry ,law.invention ,IMMUNE RECONSTITUTION ,0302 clinical medicine ,Randomized controlled trial ,law ,030212 general & internal medicine ,HIV-1-INFECTED CHILDREN ,0303 health sciences ,Multidisciplinary ,ACTIVE ANTIRETROVIRAL THERAPY ,3. Good health ,Medicine ,Off Treatment ,Poverty-related infectious diseases Infectious diseases and international health [N4i 3] ,THYMIC OUTPUT ,Viral load ,Research Article ,Science ,1-INFECTED CHILDREN ,Auto-immunity, transplantation and immunotherapy [N4i 4] ,03 medical and health sciences ,Acquired immunodeficiency syndrome (AIDS) ,medicine ,Preschool ,030304 developmental biology ,business.industry ,medicine.disease ,Clinical trial ,Immunology ,STRUCTURED TREATMENT INTERRUPTION ,business ,CD8 - Abstract
Contains fulltext : 126098.pdf (Publisher’s version ) (Open Access) OBJECTIVES: To evaluate the immunological and viral consequences of planned treatment interruptions (PTI) in children with HIV. DESIGN: This was an immunological and virological sub-study of the Paediatric European Network for Treatment of AIDS (PENTA) 11 trial, which compared CD4-guided PTI of antiretroviral therapy (ART) with continuous therapy (CT) in children. METHODS: HIV-1 RNA and lymphocyte subsets, including CD4 and CD8 cells, were quantified on fresh samples collected during the study; CD45RA, CD45RO and CD31 subpopulations were evaluated in some centres. For 36 (18 PTI, 18 CT) children, immunophenotyping was performed and cell-associated HIV-1 DNA analysed on stored samples to 48 weeks. RESULTS: In the PTI group, CD4 cell count fell rapidly in the first 12 weeks off ART, with decreases in both naive and memory cells. However, the proportion of CD4 cells expressing CD45RA and CD45RO remained constant in both groups. The increase in CD8 cells in the first 12 weeks off ART in the PTI group was predominantly due to increases in RO-expressing cells. PTI was associated with a rapid and sustained increase in CD4 cells expressing Ki67 and HLA-DR, and increased levels of HIV-1 DNA. CONCLUSIONS: PTI in children is associated with rapid changes in CD4 and CD8 cells, likely due to increased cell turnover and immune activation. However, children off treatment may be able to maintain stable levels of naive CD4 cells, at least in proportion to the memory cell pool, which may in part explain the observed excellent CD4 cell recovery with re-introduction of ART.
- Published
- 2013
21. Alzheimer's amyloid precursor protein is expressed on the surface of hematopoietic cells upon activation
- Author
-
María J. Bullido, Muñoz-Fernandez Ma, María Recuero, Fernando Valdivieso, and Manuel Fresno
- Subjects
Lymphocyte ,Cell ,Activation ,HL-60 Cells ,Lymphocyte Activation ,Monocytes ,Cell membrane ,Amyloid beta-Protein Precursor ,Immune system ,Cell surface receptor ,mental disorders ,medicine ,Amyloid precursor protein ,Cell surface marker ,Humans ,Senile plaques ,Lymphocytes ,Molecular Biology ,Protein Kinase C ,biology ,Cell Membrane ,Antibodies, Monoclonal ,Cell Biology ,Cell biology ,medicine.anatomical_structure ,Biochemistry ,biology.protein ,Immunologic Techniques ,Calcium ,Antibody ,Alzheimer's amyloid ,Granulocytes - Abstract
A4-amyloid is the major component of senile plaques and neurofibrillary tangles found in the brain of patients suffering Alzheimer's disease. This 39–42 amino acid peptide is derived from a larger precursor protein (APP). Since APP gene encodes for a putative membrane protein, the study of APP expression at the cell surface may provide useful data for understanding its physiological function. In this report, we present data on APP expression, that was detected by APP specific mAbs in cells of the hematopoietic system. APP was weakly expressed on the cell surface of resting human lymphocytes and monocytes, but it could be induced to the surface of those cells upon stimulation. The cell activators capable of inducing APP membrane expression comprehended mitogenic lectins, calcium ionophores, phosphatase inhibitors, and anti μ-chain or anti-CD3 antibodies in B and T cells, respectively. Interestingly, phorbol esters were able to induce APP membrane expression in monocytic, but not in lymphoid cells. In contrast to lymphocytes and monocytes, granulocytes never expressed cell surface or cytoplasmic APP, even after the activation. The induction of membrane APP in response to lymphocyte activation signals, including antibodies to the antigen receptor of B and T cells, raises the possibility that APP might play the role of a cell surface receptor in the immune system.
- Published
- 1996
- Full Text
- View/download PDF
22. Patients on a combined antiretroviral therapy after maraviroc clinical test show no immunovirological impairment
- Author
-
Genebat, Miguel, Pulido, Ildefonso, Romero-Sánchez, M. Concepción, González-Serna, Alejandro, Ferrando-Martínez, Sara, Machmach, Kawthar, Pacheco, Yolanda M., Muñoz-Fernández, Mª Ángeles, Ruiz-Mateos, Ezequiel, and Leal, Manuel
- Published
- 2012
- Full Text
- View/download PDF
23. Carbosilane dendrimers NN8 and NN16 form a stable complex with siGAG1
- Author
-
Shcharbin, Dzmitry, Pedziwiatr, Elzbieta, Nowacka, Olga, Kumar, Mayank, Zaborski, Marian, Ortega, Paula, Javier de la Mata, F., Gómez, Rafael, Muñoz-Fernandez, Ma Angeles, and Bryszewska, Maria
- Published
- 2011
- Full Text
- View/download PDF
24. High plasma fractalkine (CX3CL1) levels are associated with severe liver disease in HIV/HCV co-infected patients with HCV genotype 1
- Author
-
García-Álvarez, Mónica, Berenguer, Juan, Guzmán-Fulgencio, María, Micheloud, Dariela, Catalán, Pilar, Muñoz-Fernandez, Mª Ángeles, Álvarez, Emilio, and Resino, Salvador
- Published
- 2011
- Full Text
- View/download PDF
25. Discordance rates between Trofile ® test and short-term virological response to maraviroc
- Author
-
Genebat, Miguel, Ruiz-Mateos, Ezequiel, González-Serna, Alejandro, Pulido, Ildefonso, Muñoz-Fernández, Mª Ángeles, Ferrando-Martínez, Sara, and Leal, Manuel
- Published
- 2011
- Full Text
- View/download PDF
26. Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children
- Author
-
Cressey, Tr, Green, H, Khoo, S, Treluyer, Jm, Compagnucci, A, Saidi, Y, Lallemant, M, Gibb, Dm, Burger, Dm, Collaborators: Aboulker JP, Paediatric European Network for Treatment of AIDS II Study G. r. o. u. p., Babiker, A, Blanche, S, Bohlin, Ab, Butler, K, Castelli Gattinara, G, Clayden, P, Darbyshire, Jh, Debré, M, de Groot, R, della Negra, M, Duicelescu, D, Giaquinto, C, Grosch Wörner, I, Kind, C, Levy, J, Lyall, H, Marczynska, M, Mellado Peña MJ, Nadal, D, Niehues, T, Peckham, C, Ramos Amador JT, Rosado, L, Rudin, C, Scherpbier, Hj, Sharland, M, Stevanovic, M, Tovo, Pier Angelo, Tudor Williams, G, Valerius, N, Walker, As, Wintergerst, U, Aboulker, Jp, Harper, L, Klein, N, Mofenson, L, Moye, J, Saïdi, Y, Jacqz Aigrain, E, Tréluyer, Jm, Clerici, M, De Rossi, A, Ngo Giang Huong, N, Muñoz Fernandez MA, Pillay, D, Hill, C, Lepage, P, Pozniak, A, Vella, S, Eliette, V, Hadjou, G, Léonardo, S, Pitrou, C, Riault, Y, Buck, L, Farrelly, L, Johnson, D, Taylor, C, Chalermpantmetagul, S, Peongjakta, R, Chailert, S, Fregonese, F, Jourdain, G, Butler, D, Carlton, C, Collins, D, Kao, G, Van Buskirk, S, Watson, S, Corradini, S, Floret, D, Laplace, J, Monpoux, F, Cottalorda, J, Lefebvre, Jc, Mellul, S, Boudjoudi, N, Firtion, G, Faye, A, Beniken, D, Damond, F, Tricoire, J, Krivine, A, Chaix, Ml, Notheis, G, Strotmann, G, Schlieben, S, Rampon, O, Zanchetta, M, Rosso, R, Repeto, E, Vitale, F, Martino, A, Bernardi, S, Mazza, A, Rossetti, G, Dobosz, S, Oldakowska, A, Popielska, J, Kaflik, M, Stanczak, J, Stanczac, T, González Tomé MI, Delgado García, R, José Mellado Peña, M, Martín Fontelos, P, Piñeiro Pérez, R, Alimenti, A, Penin, M, Gurbindo, D, Navarro Gomez ML, Jimenez, Jl, Prieto, C, de José Gómez MI, García Rodriguez MC, Moreno Pérez, D, Núñéz Cuadros, E, Asensi Botet, F, Pérez, A, Pérez Tamarit MD, Kalhert, C, Schupbach, J, Bunupuradah, T, Ananworanich, J, Phanuphak, P, Intasan, J, Ubolyam, S, Kanjanavanit, S, Namwong, T, Foster, C, Hamadache, D, Campbell, S, Hanley, C, Walsh, C, Kaye, S, Seery, P, Novelli, V, Shingadia, D, Flynn, J, Clapson, M, Jacobsen, M, Mcmaster, P, Hawkes, E, Liebeschuetz, S, Sodeinde, O, Wong, S, Walsh, S, Heath, Y, Weiner, L, Famiglietti, M, Rana, S, Yu, P, Roa, J, Puga, A, Haerry, A, Regazzi, M, Villani, S, Gibbons, S, Jullien, V, Rey, E, Treluye, Jm, Rodríguez Nóvoa, S, Tawon, Y., University of Zurich, and Green, H
- Subjects
Cyclopropanes ,Male ,Time Factors ,Infectious diseases and international health [NCEBP 13] ,HIV Infections ,Drug resistance ,Pharmacology ,THERAPY ,PROPHYLAXIS ,2726 Microbiology (medical) ,chemistry.chemical_compound ,Plasma ,immune system diseases ,Medicine ,Child ,Reverse-transcriptase inhibitor ,RESISTANCE, THERAPY, EXPOSURE, PHARMACOGENETICS, PROPHYLAXIS ,virus diseases ,Drug holiday ,Viral Load ,Infectious Diseases ,Alkynes ,Child, Preschool ,Reverse Transcriptase Inhibitors ,Female ,Viral load ,medicine.drug ,Microbiology (medical) ,medicine.medical_specialty ,Efavirenz ,Nevirapine ,Adolescent ,CD4-CD8 Ratio ,610 Medicine & health ,Article ,Invasive mycoses and compromised host [N4i 2] ,Internal medicine ,Drug Resistance, Viral ,Humans ,Protease inhibitor (pharmacology) ,EXPOSURE ,PHARMACOGENETICS ,business.industry ,Poverty-related infectious diseases [N4i 3] ,2725 Infectious Diseases ,Benzoxazines ,CD4 Lymphocyte Count ,Regimen ,chemistry ,Withholding Treatment ,10036 Medical Clinic ,Mutation ,HIV-1 ,Microbial pathogenesis and host defense [UMCN 4.1] ,business ,RESISTANCE - Abstract
Contains fulltext : 71467.pdf (Publisher’s version ) (Open Access) BACKGROUND: The optimum strategy for stopping treatment with drugs that have different half-lives in a combination regimen to minimize the risk of selecting drug-resistant viruses remains unknown. We evaluated drug concentrations in plasma, human immunodeficiency virus (HIV) load, and development of drug resistance after a planned treatment interruption of a nonnucleoside reverse-transcriptase inhibitor (NNRTI)-containing regimen in HIV type 1-infected children. METHODS: Children with viral loads or =30% (for children aged 2-6 years) or CD4 cell percentages > or =25% and CD4 cell counts > or =500 cells/microL (for children aged 7-15 years) were randomized to either a planned treatment interruption or to continuous therapy. In the planned treatment interruption arm, either (1) treatment with nevirapine or efavirenz was stopped, and treatment with the remaining drugs was continued for 7-14 days, or (2) nevirapine or efavirenz were replaced by a protease inhibitor, and all drugs were stopped after 7-14 days. Sampling for determination of plasma drug concentrations, measurement of viral load, and drug resistance testing was scheduled at day 0, day 7 (drug concentrations only), day 14, and day 28 after interruption of treatment with an NNRTI. RESULTS: Treatment with an NNRTI was interrupted for 35 children (20 were receiving nevirapine, and 15 were receiving efavirenz). Median time from NNRTI cessation to stopping all drugs was 9 days (range, 6-15 days) for nevirapine and 14 days (range, 6-18 days) for efavirenz. At 7 days, 1 (5%) of 19 and 4 (50%) of 8 children had detectable nevirapine and efavirenz concentrations, respectively; efavirenz remained detectable in 3 (25%) of 12 children at 14 days. At 14 days, viral load was > or =50 copies/mL in 6 of 16 children interrupting treatment with nevirapine (range, 52-7000 copies/mL) and in 2 of 12 children interrupting treatment with efavirenz (range, 120-1600 copies/mL). No new NNRTI mutations were observed. CONCLUSIONS: In children with virological suppression who experienced interruption of treatment with an NNRTI, staggered or replacement stopping strategies for a median of 9 days for nevirapine and 14 days for efavirenz were not associated with the selection of NNRTI resistance mutations.
- Published
- 2008
27. WNT Signaling Suppression in the Senescent Human Thymus
- Author
-
Ferrando-Martínez, Sara, primary, Ruiz-Mateos, Ezequiel, additional, Dudakov, Jarrod A., additional, Velardi, Enrico, additional, Grillari, Johannes, additional, Kreil, David P., additional, Muñoz-Fernandez, Mª Ángeles, additional, van den Brink, Marcel R. M., additional, and Leal, Manuel, additional
- Published
- 2014
- Full Text
- View/download PDF
28. Carbosilane Dendrimers are a Non-Viral Delivery System for Antisense Oligonucleotides: Characterization of Dendriplexes
- Author
-
Pedziwiatr-Werbicka, Elzbieta, primary, Shcharbin, Dzmitry, additional, Maly, Jan, additional, Maly, Marek, additional, Zaborski, Marian, additional, Gabara, Barbara, additional, Ortega, Paula, additional, de la Mata, F. Javier, additional, Gómez, Rafael, additional, Muñoz-Fernandez, Ma Angeles, additional, Klajnert, Barbara, additional, and Bryszewska, Maria, additional
- Published
- 2012
- Full Text
- View/download PDF
29. Dendrimers as topical microbicides with activity against HIV
- Author
-
Jiménez, José Luis, primary, Pion, Marjorie, additional, Mata, F. Javier de la, additional, Gomez, Rafael, additional, Muñoz, Eduardo, additional, Leal, Manuel, additional, and Muñoz-Fernandez, Ma Angeles, additional
- Published
- 2012
- Full Text
- View/download PDF
30. Carbosilane dendrimers peripherally functionalized with dansyl fluorescence tags and their cellular internalization studies
- Author
-
Ortega, Paula, primary, Serramía, Ma Jesús, additional, Samaniego, Rafael, additional, de la Mata, F. Javier, additional, Gomez, Rafael, additional, and Muñoz-Fernandez, Ma Angeles, additional
- Published
- 2009
- Full Text
- View/download PDF
31. Binding Properties of Water-Soluble Carbosilane Dendrimers
- Author
-
Pedziwiatr, Elzbieta, primary, Shcharbin, Dzmitry, additional, Chonco, Louis, additional, Ortega, Paula, additional, Javier de la Mata, F., additional, Gómez, Rafael, additional, Klajnert, Barbara, additional, Bryszewska, Maria, additional, and Muñoz-Fernandez, Ma Angeles, additional
- Published
- 2008
- Full Text
- View/download PDF
32. Amine and ammonium functionalization of chloromethylsilane-ended dendrimers. Antimicrobial activity studies
- Author
-
Ortega, Paula, primary, Copa-Patiño, Jose Luis, additional, Muñoz-Fernandez, Ma Angeles, additional, Soliveri, Juan, additional, Gomez, Rafael, additional, and de la Mata, F. Javier, additional
- Published
- 2008
- Full Text
- View/download PDF
33. Predictive factors of virological success to salvage regimens containing protease inhibitors in HIV-1 infected children
- Author
-
Larru, Beatriz, primary, de Mendoza, Carmen, additional, Bellón, José Ma, additional, de José, Ma Isabel, additional, Mellado, Ma José, additional, Soriano, Vincent, additional, Muñoz-Fernandez, Ma Angeles, additional, and Ramos, José T, additional
- Published
- 2007
- Full Text
- View/download PDF
34. Water-soluble carbosilane dendrimers protect phosphorothioate oligonucleotides from binding to serum proteins
- Author
-
Chonco, Louis, primary, Bermejo-Martín, Jesus F., additional, Ortega, Paula, additional, Shcharbin, Dzmitry, additional, Pedziwiatr, Elzbieta, additional, Klajnert, Barbara, additional, Javier de la Mata, F., additional, Eritja, Ramon, additional, Gómez, Rafael, additional, Bryszewska, Maria, additional, and Angeles Muñoz-Fernandez, Ma, additional
- Published
- 2007
- Full Text
- View/download PDF
35. WNT Signaling Suppression in the Senescent Human Thymus.
- Author
-
Ferrando-Martínez, Sara, Ruiz-Mateos, Ezequiel, Dudakov, Jarrod A., Velardi, Enrico, Grillari, Johannes, Kreil, David P., Muñoz-Fernandez, Mª Ángeles, van den Brink, Marcel R. M., and Leal, Manuel
- Subjects
THYMUS ,AGING ,ATROPHY ,WNT proteins ,GENE expression ,ANIMAL models in research - Abstract
Human thymus is completely developed in late fetal stages and its function peaks in newborns. After the first year of life, the thymus undergoes a progressive atrophy that dramatically decreases de novo T-lymphocyte maturation. Hormonal signaling and changes in the microRNA expression network are identified as underlying causes of human thymus involution. However, specific pathways involved in the age-related loss of thymic function remain unknown. In this study, we analyzed differential gene-expression profile and microRNA expression in elderly (70 years old) and young (less than 10 months old and 11 years old) human thymic samples. Our data have shown that WNT pathway deregulation through the overexpression of different inhibitors by the nonadipocytic component of the human thymus stimulates the age-related involution. These results are of particular interest because interference of WNT signaling has been demonstrated in both animal models and in vitro studies, with the three major hallmarks of thymic involution: (i) epithelial structure disruption, (ii) adipogenic process, and (iii) thymocyte development arrest. Thus, our results suggest that secreted inhibitors of the WNT pathway could be explored as a novel therapeutical target in the reversal of the age-related thymic involution. [ABSTRACT FROM PUBLISHER]
- Published
- 2015
- Full Text
- View/download PDF
36. Severe Acute Respiratory Syndrome in children: a clue to better understanding the disease and advancing towards solutions
- Author
-
Bermejo, JF, primary and Muñoz-Fernandez, MA, additional
- Published
- 2004
- Full Text
- View/download PDF
37. A new tool for the paediatric HIV research:general data from the Cohort of the Spanish Paediatric HIV Network (CoRISpe).
- Author
-
de Jose, Ma Isabel, de Ory, Santiago Jiménez, Espiau, Maria, Fortuny, Claudia, Navarro, Ma Luisa, Soler-Palacín, Pere, and Muñoz-Fernandez, Ma Angeles
- Subjects
HIV infections ,JUVENILE diseases ,PEDIATRICS ,HOSPITALS - Abstract
There are approximately from 1,100 to 1,200 HIV-infected children in a follow-up in Spain. In 2008 an open, multicentral, retrospective and prospective Cohort of the Spanish Paediatric HIV Network (CoRISpe) was founded. The CoRISpe is divided into the node 1 and node 2 representing geographically almost the whole territory of Spain. Since 2008 seventy-five hospitals have been participating in the CoRISpe. All the retrospective data of the HIV-infected children have been kept in the CoRISpe since 1995 and prospective data since 2008. In this article we are going to present the notion of CoRISpe, its role, the structure, how the CoRISpe works and the process how a child is transferred from Paediatric to Adults Units. The main objective of the CoRISpe is to contribute to furthering scientific knowledge on paediatric HIV infection by providing demographic, sociopsychological, clinical and laboratory data from HIV-infected paediatric patients. Its aim is to enable high-quality research studies on HIV-infected children. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
38. Comparative uptake of phosphorothioate oligonucleotides by human peripheral blood mononuclear cells from newborns and adults
- Author
-
Bermejo, J. F., Louis Chonco, Samaniego, R., Fernandez, G., Eritja, R., and Muñoz-Fernandez, Ma A.
39. Low unspliced cell-associated HIV RNA in early treated adolescents living with HIV on long suppressive ART.
- Author
-
Gärtner K, Domínguez-Rodríguez S, Heaney J, Gkouleli T, Grant P, Dorgham K, Sauce D, Soulie C, Busby EJ, O'Sullivan DM, Spyer M, Botha JC, Muñoz-Fernandez MA, Tagarro A, Cotugno N, Huggett JF, Klein N, Palma P, Rojo Conejo P, Foster C, Giaquinto C, Rossi P, Persaud D, De Rossi A, Marcelin AG, and Nastouli E
- Subjects
- Humans, Adolescent, Child, Cross-Sectional Studies, RNA, Anti-Retroviral Agents therapeutic use, Cytokines, DNA, Cell-Free Nucleic Acids, HIV Infections drug therapy
- Abstract
Introduction: Initiation of antiretroviral treatment (ART) in patients early after HIV-infection and long-term suppression leads to low or undetectable levels of HIV RNA and cell-associated (CA) HIV DNA and RNA. Both CA-DNA and CA-RNA, overestimate the size of the HIV reservoir but CA-RNA as well as p24/cell-free viral RNA can be indicators of residual viral replication. This study describes HIV RNA amounts and levels of cytokines/soluble markers in 40 well-suppressed adolescents who initiated ART early in life and investigated which viral markers may be informative as endpoints in cure clinical trials within this population., Methods: Forty adolescents perinatally infected with HIV on suppressive ART for >5 years were enrolled in the CARMA study. HIV DNA and total or unspliced CA-RNA in PBMCs were analyzed by qPCR/RT-qPCR and dPCR/RT-dPCR. Cell-free HIV was determined using an ultrasensitive viral load (US-VL) assay. Plasma markers and p24 were analyzed by digital ELISA and correlations between total and unspliced HIV RNA and clinical markers, including age at ART, Western Blot score, levels of cytokines/inflammation markers or HIV CA-DNA, were tested., Results: CA-RNA was detected in two thirds of the participants and was comparable in RT-qPCR and RT-dPCR. Adolescents with undetectable CA-RNA showed significantly lower HIV DNA compared to individuals with detectable CA-RNA. Undetectable unspliced CA-RNA was positively associated with age at ART initiation and Western Blot score. We found that a higher concentration of TNF-α was predictive of higher CA-DNA and CA-RNA. Other clinical characteristics like US-VL, time to suppression, or percent CD4+ T-lymphocytes were not predictive of the CA-RNA in this cross-sectional study., Conclusions: Low CA-DNA after long-term suppressive ART is associated with lower CA-RNA, in concordance with other reports. Patients with low CA-RNA levels in combination with low CA-DNA and low Western Blot scores should be further investigated to characterize candidates for treatment interruption trials. Unspliced CA-RNA warrants further investigation as a marker that can be prioritized in paediatric clinical trials where the sample volume can be a significant limitation., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision., (Copyright © 2024 Gärtner, Domínguez-Rodríguez, Heaney, Gkouleli, Grant, Dorgham, Sauce, Soulie, Busby, O’Sullivan, Spyer, Botha, Muñoz-Fernandez, Tagarro, Cotugno, Huggett, Klein, Palma, Rojo Conejo, Foster, Giaquinto, Rossi, Persaud, De Rossi, Marcelin and Nastouli.)
- Published
- 2024
- Full Text
- View/download PDF
40. Immune modulation via dendritic cells by the effect of Thymosin-alpha-1 on immune synapse in HCMV infection.
- Author
-
Espinar-Buitrago MS, Vazquez-Alejo E, Magro-Lopez E, Tarancon-Diez L, Leal M, and Muñoz-Fernandez MA
- Subjects
- Humans, Thymalfasin pharmacology, Hepatitis A Virus Cellular Receptor 2 metabolism, Leukocytes, Mononuclear metabolism, Tumor Necrosis Factor-alpha metabolism, Interleukin-2 metabolism, Programmed Cell Death 1 Receptor metabolism, Dendritic Cells, Synapses, Thymosin metabolism
- Abstract
Tα1 (Thymosin-alpha-1) is a thymus-derived hormone that has been demonstrated to be effective on diverse immune cell subsets. The objective of this study was to determine the in vitro immunomodulatory effect of Tα1 in human cytomegalovirus (HCMV) infection. Dendritic cells (DCs) were isolated from peripheral blood mononuclear cells (PBMCs) by negative selection and cultured in the presence or absence of Tα1. The immunophenotyping of DCs was characterised by multiparametric flow cytometry assessing CD40, CD80, TIM-3 and PDL-1 markers, as well as intracellular TNFα production. Then, autologous CD4+ or CD8+ T-Lymphocytes (TLs) isolated by negative selection from PBMCs were co-cultured with DCs previously treated with Tα1 in the presence or absence of HCMV. Intracellular TNFα, IFNγ, IL-2 production, CD40-L and PD-1 expression were assessed through immunophenotyping, and polyfunctionality in total TLs and memory subsets were evaluated. The results showed that Tα1 increased CD40, CD80, TIM-3 and TNFα intracellular production while decreasing PDL-1 expression, particularly on plasmacytoid dendritic cells (pDCs). Therefore, Tα1 modulated the production of TNFα, IFNγ and IL-2 in both total and memory subsets of CD4+ and CD8+ TLs by upregulating CD40/CD40-L and downregulating PDL-1/PD-1 expression. Our study concludes that Tα1 enhances antigen-presenting capacity of DCs, improves TLs responses to HCMV infection, and enhances the polyfunctionality of CD8+ TLs. Consequently, Tα1 could be an alternative adjuvant for use in therapeutic cell therapy for immunocompromised patients., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
41. The use of alpha 1 thymosin as an immunomodulator of the response against SARS-Cov2.
- Author
-
Espinar-Buitrago MS, Tarancon-Diez L, Vazquez-Alejo E, Magro-Lopez E, Genebat M, Romero-Candau F, Leal M, and Muñoz-Fernandez MA
- Abstract
Background: Since the beginning of SARS-CoV2 pandemic, the mortality rate among elderly patients (60-90 years) has been around 50%, so age has been a determining factor of a worse COVID-19 prognosis. Associated with age, the thymic function involution and depletion plays an important role, that could be related to a dysregulated and ineffective innate and adaptive immune response against SARS-CoV2. Our study aims to further in vitro effect of human Thymosin-alpha-1 (α1Thy) treatment on the immune system in population groups with different thymic function levels in the scenario of SARS-CoV2 infection., Results: Activation markers such as CD40, CD80 and TIM-3 were upregulated in α1Thy presence, especially in plasmacytoid dendritic cells (pDCs) and, with increased TNFα production was observed compared to untreated condition. Co-cultures of CD4 + and CD8 + T cells with DCs treated with α1Thy in response to SARS-CoV2 peptides showed a decrease in the cytokine production compared to the condition without α1Thy pre-treated. A decrease in CD40L activation co-receptor expression in CD8 + LTs was also observed, as well as an increase in PD1 in CD4 + TLs expression in both age groups. In fact, there are no age-related differences in the immunomodulatory effect of the hormone, and it seems that effector memory and terminally differentiated memory T lymphocyte subsets were the most actively influenced by the immunomodulatory α1Thy effect. Finally, the polyfunctionality measured in SARS-CoV2 Specific-T cells response was maintained in α1Thy presence in total and memory subpopulations CD4 + and CD8 + T-cells, despite decreased proinflammatory cytokines production., Conclusion: The hormone α1Thy could reduce, through the modulation of DCs, the amount of proinflammatory cytokines produced by T cells. Moreover, α1Thy improve lymphocyte functionality and could become a beneficial therapeutic alternative as an adjuvant in SARS-CoV2 treatment either in the acute phase after infection or reinfection. In addition, the effect on the T immune response means that α1Thy can be incorporated into the vaccination regimen, especially in the most immunologically vulnerable individuals such as the elderly., Subjects: Thymosin alpha 1, Dendritic cells, SARS-CoV2-specific T cells response, Immunomodulation., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
42. Vaginal neutrophil infiltration is contingent on ovarian cycle phase and independent of pathogen infection.
- Author
-
Latorre MC, Gómez-Oro C, Olivera-Valle I, Blazquez-Lopez E, Gallego-Valle J, Ibañez-Escribano A, Casesnoves P, González-Cucharero C, Muñoz-Fernandez MA, Sanz L, Vaquero J, Martín-Rabadań P, Perez-Milan F, and Relloso M
- Subjects
- Male, Female, Mice, Animals, Neutrophil Infiltration, Vagina, Menstrual Cycle, Endothelial Cells, Semen
- Abstract
The mucosa of the female reproductive tract must reconcile the presence of commensal microbiota and the transit of exogenous spermatozoa with the elimination of sexually transmitted pathogens. In the vagina, neutrophils are the principal cellular arm of innate immunity and constitute the first line of protection in response to infections or injury. Neutrophils are absent from the vaginal lumen during the ovulatory phase, probably to allow sperm to fertilize; however, the mechanisms that regulate neutrophil influx to the vagina in response to aggressions remain controversial. We have used mouse inseminations and infections of Neisseria gonorrhoeae , Candida albicans , Trichomonas vaginalis , and HSV-2 models. We demonstrate that neutrophil infiltration of the vaginal mucosa is distinctively contingent on the ovarian cycle phase and independent of the sperm and pathogen challenge, probably to prevent sperm from being attacked by neutrophils. Neutrophils extravasation is a multi-step cascade of events, which includes their adhesion through selectins (E, P and L) and integrins of the endothelial cells. We have discovered that cervical endothelial cells expressed selectin-E (SELE, CD62E) to favor neutrophils recruitment and estradiol down-regulated SELE expression during ovulation, which impaired neutrophil transendothelial migration and orchestrated sperm tolerance. Progesterone up-regulated SELE to restore surveillance after ovulation., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Latorre, Gómez‐Oro, Olivera‐Valle, Blazquez‐Lopez, Gallego‐Valle, Ibañez‐Escribano, Casesnoves, González‐Cucharero, Muñoz‐Fernandez, Sanz, Vaquero, Martín‐Rabadań, Perez‐Milan and Relloso.)
- Published
- 2022
- Full Text
- View/download PDF
43. Safety and efficacy of G2-S16 dendrimer as microbicide in healthy human vaginal tissue explants.
- Author
-
Rodríguez-Izquierdo I, Serramía MJ, Gómez R, Espinosa G, Genebat M, Leal M, and Muñoz-Fernandez MA
- Subjects
- Female, HIV-1, Humans, Vagina, Anti-Infective Agents adverse effects, Dendrimers adverse effects
- Abstract
Background: The absence of an effective treatment and vaccine in HIV-1 pandemic place preventive strategies such as safety and effective microbicide development as a central therapeutic approach to control HIV-1 pandemic nowadays., Results: Studies of cytotoxicity, immune population status, inflammation or tissue damage and mainly prophylactic inhibition of HIV-1 infection in vaginal human explants demonstrate the biosafety and effectivity of G2-S16 dendrimer. Human explants treated with G2-S16 dendrimer or treated and HIV-1 infected do not presented signs of irritation, inflammation, immune activation or T cell populations deregulation., Conclusions: Herein we conclude that G2-S16 dendrimer has demonstrated sufficient efficacy, biosafety, effectivity and behavior in the closest to the real-life condition model represented by the human healthy donor vaginal tissue explants, to raise G2-S16 dendrimer as a promising candidate to clinical trials to develop an effective microbicide against HIV-1 infection., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
44. Association of heterozygous CCR5Δ32 deletion with survival in HIV-infection: A cohort study.
- Author
-
Ruiz-Mateos E, Tarancon-Diez L, Alvarez-Rios AI, Dominguez-Molina B, Genebat M, Pulido I, Abad MA, Muñoz-Fernandez MA, and Leal M
- Subjects
- Adult, Cohort Studies, Female, Genotype, HIV Infections epidemiology, HIV Infections virology, Humans, Kaplan-Meier Estimate, Male, Prognosis, Risk Factors, Viral Load, Young Adult, HIV Infections genetics, HIV Infections mortality, HIV-1, Heterozygote, Receptors, CCR5 genetics, Sequence Deletion
- Abstract
The role of a 32 base pair deletion in the CCR5 gene (CCR5Δ32) in HIV-disease progression and response to combined antiretroviral therapy (cART) is well established. However, the impact of CCR5Δ32 in the long-term survival pre-cART and after cART introduction in a large cohort of HIV-infected patients is unknown. We analyzed the association of CCR5Δ32 deletion in the long-term survival of HIV-infected patients recruited between June 1981 and October 2016 (n = 1006). Clinical and epidemiological variables were recorded and CCR5Δ32 deletion was assessed by PCR and electrophoretic analysis. The association of CCR5Δ32 deletion with the time to death was analyzed by Log-Rank tests and Cox Regression models. The CCR5 WT/Δ32 prevalence was 13.4% (n = 135). We did not find any homozygous subject for CCR5Δ32 deletion. AIDS (n = 85, 41.5%) and non-AIDS (n = 87, 42.4%) events were the main causes of 205 deaths. CCR5Δ32 deletion was independently associated with survival (p = 0.022; hazard ratio (HR): 0.572, confidence interval (CI) [0.354-0.923]), after adjusting by HIV diagnosis before 1997, age at diagnosis, being on cART, risk of transmission, nadir CD4
+ T-cell counts and CDC stage C. This result was reproduced when the analysis was restricted to patients on cART (p = 0.045; HR: 0.530 [0.286-0.985]). These results confirm the protective role of CCR5Δ32, and extend it to the long-term survival in a large cohort of HIV-infected patients. Beyond its antiviral effect, CCR5Δ32 enhanced the long-term survival of patients on cART., (Copyright © 2017 Elsevier B.V. All rights reserved.)- Published
- 2018
- Full Text
- View/download PDF
45. Sex Hormones Coordinate Neutrophil Immunity in the Vagina by Controlling Chemokine Gradients.
- Author
-
Lasarte S, Samaniego R, Salinas-Muñoz L, Guia-Gonzalez MA, Weiss LA, Mercader E, Ceballos-García E, Navarro-González T, Moreno-Ochoa L, Perez-Millan F, Pion M, Sanchez-Mateos P, Hidalgo A, Muñoz-Fernandez MA, and Relloso M
- Subjects
- Adult, Animals, Candida albicans immunology, Candidiasis immunology, Cell Movement, Cells, Cultured, Chemokines genetics, Female, Gene Expression Regulation immunology, Humans, Mice, Mice, Knockout, Receptors, Interleukin-8B genetics, Receptors, Interleukin-8B metabolism, Vagina immunology, Chemokines metabolism, Estrogens pharmacology, Neutrophils immunology, Neutrophils physiology, Progesterone pharmacology, Vagina cytology
- Abstract
Estradiol-based contraceptives and hormonal replacement therapy predispose women to Candida albicans infections. Moreover, during the ovulatory phase (high estradiol), neutrophil numbers decrease in the vaginal lumen and increase during the luteal phase (high progesterone). Vaginal secretions contain chemokines that drive neutrophil migration into the lumen. However, their expression during the ovarian cycle or in response to hormonal treatments are controversial and their role in vaginal defense remains unknown.To investigate the transepithelial migration of neutrophils, we used adoptive transfer of Cxcr2(-/-) neutrophils and chemokine immunofluorescence quantitative analysis in response to C. albicans vaginal infection in the presence of hormones.Our data show that the Cxcl1/Cxcr2 axis drives neutrophil transepithelial migration into the vagina. Progesterone promotes the Cxcl1 gradient to favor neutrophil migration. Estradiol disrupts the Cxcl1 gradient and favors neutrophil arrest in the vaginal stroma; as a result, the vagina becomes more vulnerable to pathogens., (© The Author 2015. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.)
- Published
- 2016
- Full Text
- View/download PDF
46. A Conserved GPG-Motif in the HIV-1 Nef Core Is Required for Principal Nef-Activities.
- Author
-
Martínez-Bonet M, Palladino C, Briz V, Rudolph JM, Fackler OT, Relloso M, Muñoz-Fernandez MA, and Madrid R
- Subjects
- HIV-1 genetics, HIV-1 pathogenicity, HeLa Cells, Humans, Protein Structure, Tertiary, Structure-Activity Relationship, T-Lymphocytes virology, nef Gene Products, Human Immunodeficiency Virus chemistry, nef Gene Products, Human Immunodeficiency Virus genetics, Amino Acid Motifs, nef Gene Products, Human Immunodeficiency Virus physiology
- Abstract
To find out new determinants required for Nef activity we performed a functional alanine scanning analysis along a discrete but highly conserved region at the core of HIV-1 Nef. We identified the GPG-motif, located at the 121-137 region of HIV-1 NL4.3 Nef, as a novel protein signature strictly required for the p56Lck dependent Nef-induced CD4-downregulation in T-cells. Since the Nef-GPG motif was dispensable for CD4-downregulation in HeLa-CD4 cells, Nef/AP-1 interaction and Nef-dependent effects on Tf-R trafficking, the observed effects on CD4 downregulation cannot be attributed to structure constraints or to alterations on general protein trafficking. Besides, we found that the GPG-motif was also required for Nef-dependent inhibition of ring actin re-organization upon TCR triggering and MHCI downregulation, suggesting that the GPG-motif could actively cooperate with the Nef PxxP motif for these HIV-1 Nef-related effects. Finally, we observed that the Nef-GPG motif was required for optimal infectivity of those viruses produced in T-cells. According to these findings, we propose the conserved GPG-motif in HIV-1 Nef as functional region required for HIV-1 infectivity and therefore with a potential interest for the interference of Nef activity during HIV-1 infection.
- Published
- 2015
- Full Text
- View/download PDF
47. Use of carbosilane dendrimer to switch macrophage polarization for the acquisition of antitumor functions.
- Author
-
Perisé-Barrios AJ, Gómez R, Corbí AL, de la Mata J, Domínguez-Soto A, and Muñoz-Fernandez MA
- Subjects
- Biomarkers metabolism, Cell Polarity drug effects, Cell Proliferation drug effects, Cells, Cultured, Dendrimers pharmacology, Humans, Immunotherapy, Interleukin-10 metabolism, K562 Cells, Lipopolysaccharides toxicity, Macrophages cytology, Macrophages drug effects, Macrophages metabolism, Monocytes cytology, Neoplasms immunology, Neoplasms therapy, Organosilicon Compounds pharmacology, Phagocytosis drug effects, Phosphorylation drug effects, STAT3 Transcription Factor metabolism, Dendrimers chemistry, Organosilicon Compounds chemistry, Silanes chemistry
- Abstract
Tumor microenvironment favors the escape from immunosurveillance by promoting immunosuppression and blunting pro-inflammatory responses. Since most tumor-associated macrophages (TAM) exhibit an M2-like tumor cell growth promoting polarization, we have studied the role of 2G-03NN24 carbosilane dendrimer in M2 macrophage polarization to evaluate the potential application of dendrimers in tumor immunotherapy. We found that the 2G-03NN24 dendrimer decreases LPS-induced IL-10 production from in vitro generated monocyte-derived M2 macrophages, and also switches their gene expression profile towards the acquisition of M1 polarization markers (INHBA, SERPINE1, FLT1, EGLN3 and ALDH1A2) and the loss of M2 polarization-associated markers (EMR1, IGF1, FOLR2 and SLC40A1). Furthermore, 2G-03NN24 dendrimer decreases STAT3 activation. Our results indicate that the 2G-03NN24 dendrimer can be a useful tool for antitumor therapy by virtue of its potential ability to limit the M2-like polarization of TAM.
- Published
- 2015
- Full Text
- View/download PDF
48. [Psychosocial aspects in a cohort of vertically transmitted human immunodeficiency virus-infected adolescents].
- Author
-
García-Navarro C, García I, Medín G, Ramos-Amador JT, Navarro-Gómez M, Mellado-Peña MJ, Gómez MI, Cortés M, Zamora Crespo B, Muñoz-Fernandez MA, Gamero DB, and González-Tomé MI
- Subjects
- Adolescent, Child, Female, HIV Infections complications, Humans, Male, Mental Disorders epidemiology, Mental Disorders etiology, Prevalence, Young Adult, HIV Infections psychology, HIV Infections transmission, Infectious Disease Transmission, Vertical
- Abstract
Introduction: Thanks to advances in antiretroviral treatment, children with HIV infections through vertical transmission have improved their life expectancy. However, new challenges have emerged. We propose this study in order to determine the psychosocial aspects and knowledge of infections in a cohort of adolescents with vertically transmitted HIV infections., Methods: Patients with vertically-acquired HIV infection between 12 and 19 years old were included. Data were obtained through semi-structured interviews and a Strengths and Difficulties Questionnaire for emotional and behavioral disorders screening., Results: We evaluated 96 patients (58% females) with a median age of 15 years (11-19.1) and a median age at diagnosis of 1.70 years (0-12.2). The median CD4 count was 626cells/mm(3) (132-998), and the viral load was<50cp/ml in 72% of patients. Among them, 90% attended school and 60% repeated at least one course. Although 81% of them knew of their diagnosis, only 30% understood their disease, with 18.2% having discussed it with friends. Six unwanted pregnancies occurred during the study period. Strengths and Difficulties Questionnaire showed hyperactivity risk in 33%., Conclusion: A high percentage of adolescents show difficulties in several areas (disease knowledge, peer relationship, school failure...) that can have an impact on their adult lives. Further studies are needed to evaluate their origin and development in depth, as well as interventions to modify this situation., (Copyright © 2013 Elsevier España, S.L.U. y Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
49. HIV-1 induces B-cell activation and class switch recombination via spleen tyrosine kinase and c-Jun N-terminal kinase pathways.
- Author
-
Perisé-Barrios AJ, Correa-Rocha R, Alvarez S, Muñoz-Fernandez MA, and Pion M
- Subjects
- B-Lymphocytes virology, Cell Proliferation, Cells, Cultured, Host-Pathogen Interactions, Humans, Syk Kinase, B-Lymphocytes immunology, HIV-1 immunology, Immunoglobulin Class Switching, Intracellular Signaling Peptides and Proteins metabolism, JNK Mitogen-Activated Protein Kinases metabolism, Lymphocyte Activation, Protein-Tyrosine Kinases metabolism, Signal Transduction
- Abstract
Objective: Patients infected by the HIV type 1 (HIV-1) frequently show a general deregulation of immune system. A direct influence of HIV-1 particles on B-cell activation, proliferation and B-cell phenotype alterations has been recently described. Moreover, expression of activation-induced cytidinedeaminase (AID) mRNA, which is responsible for class switch recombination (CSR) and somatic hypermutation (SHM), was reported to be overexpressed in B cells exposed to HIV-1., Design: Study of primary human B cells in an in-vitro model., Methods: In the current study, we evaluated which signalling pathways are activated in primary B cells after a direct contact with HIV-1 particles in vitro using different kinase inhibitors., Results: Here, we report that B-cell activation together with the increase of AID mRNA expression and the subsequent class switch recombination (CSR) in HIV-exposed B cells occurred through spleen tyrosine kinase (SYK) and c-Jun N-terminal kinase (JNK) pathways., Conclusion: Therefore, we showed that HIV-1 could directly induce primary B-cell deregulation via SYK/B-cell receptor (BCR) engagement, and that activation was followed by the JNK pathway activation. To our knowledge, these data provide the first evidence that SYK/BCR activation was the first step for B-cell activation and CSR mechanism after HIV-1 stimulation in a T-cell-free context., (2014 Wolters Kluwer Health | Lippincott Williams & Wilkins)
- Published
- 2014
- Full Text
- View/download PDF
50. Interference of cationic polymeric nanoparticles with clinical chemistry tests--clinical relevance.
- Author
-
Shcharbin D, Shcharbina N, Milowska K, de la Mata FJ, Muñoz-Fernandez MA, Mignani S, Gomez-Ramirez R, Majoral JP, and Bryszewska M
- Subjects
- Clinical Chemistry Tests, Phosphorus chemistry, Silanes chemistry, Dendrimers chemistry, Nanoparticles chemistry, Serum chemistry
- Abstract
The development of medical nanosystems requires knowledge of their behavior in vivo. Clinical chemistry tests are widely used to estimate the systemic toxicity of nanoparticles. In this paper we have explored the impact of small positively charged nanoparticles-poly(amidoamine), phosphorous and carbosilane dendrimers - on biochemical parameters of standardized serum in vitro. All the dendrimers could shift the main biochemical parameters. Thus, in the case of patients having the normal, but 'boundary', values of biochemical parameters, nanoparticle-induced changes can be wrongly interpreted as evidence of some dysfunctions (hepatic, renal, etc.). Moreover, the effects of nanoparticles of metals, carbon nanotubes, quantum dots, fullerenes, dendrimers having been sized up to 4000 nm and the hundreds of reactive groups, can be significantly higher. Thus, preliminary evaluation of any nanomaterial in vitro is required in clinical chemistry tests before its application in vivo to draw the correct conclusions and benefit animals., (Copyright © 2014 Elsevier B.V. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.